Trump’s 2018 budget will squeeze civilian science agencies
By David Malakoff,
Science
| 02. 27. 2017
The chunk of the federal budget that includes most of the U.S. government’s spending on basic science would shrink by 10.5% in 2018 under a plan outlined today by President Donald Trump and administration officials.
It is unlikely that all civilian science budgets would see cuts under the proposal—and some could even get increases. But the spending blueprint, which would have to be approved by Congress, highlights the financial pressures that civilian research agencies will face as Trump and the Republican majority in both houses of Congress attempt to carry out campaign promises to raise defense spending while reining in the rest of federal spending.
White House officials said today that they will ask Congress to increase discretionary defense spending by $54 billion, to $603 billion, in the 2018 fiscal year which begins 1 October. They expect to pay for that increase by cutting an equivalent amount from nondefense discretionary spending—the part of the budget that includes major basic research funders. That means a potential squeeze on the $31 billion National Institutes of Health, the $7 billion...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...